Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 Open-Label Single-Arm Study of Tysabri After Failure of Gilenya or BRACET in Relapsing Multiple Sclerosis
2013-005586-39Phase 4Terminated
- Sponsor
- Biogen
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Proportion of subjects with no evidence of disease activity (NEDA) at Year 1. Started Sep 2014; status: terminated.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-005586-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005586-39.